This is a Phase 3 study of rozanolixizumab in anti-AChR or
anti-MuSK autoantibody-positive patients with generalized MG who
experience moderate to severe symptoms and are being considered for
treatment with IVIg or PEX. The primary objective of the study is to
demonstrate the clinical efficacy of rozanolixizumab in patients with
generalized Myasthenia Gravis.
participants will be consented and enrolled by the Penn PI or Sub-I. Referrals
will be accepted but we plan to recruit patients from within Penn Medicine clinics.
Study Identifier: 833604
Contact the research team to learn more about this study.